Effect of CD08100/02 3% gel versus placebo gel in subjects presenting with papulopustular rosacea over a 6-week treatment period.

Galderma R&D SNC0 个研究点开始时间: 2011年9月7日最近更新: 2012年4月24日

适应症

试验速览

暂无简介。

•1. The subject is a male or female adult aged of at least 18 years;
•2. The subject presents with moderate to severe PPR characterized by the presence of at least 15 inflammatory lesions (papules and/or pustules) on the whole face except the central part of the face (nose, chin and middle forehead);
•Are the trial subjects under 18? no
•Number of subjects for this age range:
•F.1.2 Adults (18-64 years) yes
•F.1.2.1 Number of subjects for this age range
•F.1.3 Elderly (>=65 years) yes
•F.1.3.1 Number of subjects for this age range 50

•1. The subject has a particular form of rosacea or rosacea like syndrome: severe forms (rosacea conglobata or fulminans), corticosteroid induced rosacea or isolated pustulosis of the chin, facial erythrosis of known origin other than rosacea (known carcinoid syndrome, dysthyroidism, mastocytose, serotonin syndrome, lupus erythematosis) or peri-oral dermatitis;
•2. The number of inflammatory or non inflammatory lesions on one half-face is greater than twice the number on the other half-face.
•3. The subject has a severe erythema (grade more or equal to 3) or an erythema that, according to the Investigator, does not allow distinguishing papules and pustules.

发起方

Galderma R&D SNC